A major goal of translational research is to improve the therapeutic response in patients with cancer. We are using our ongoing clinical trials as a bridge between our preclinical and translational studies.
The studies completed thus far have provided us with valuable insights into the role of innate immunity in immune-mediated tumor cell killing as a result of targeted radiation generating sterile inflammation. They have also prompted us to exploit the potential of a novel drug delivery platform to release anti-cancer agents upon activation by RT at the tumor target and its prospect to generate anti-tumor immune responses. Future studies on these topics will warrant a deeper understanding of the mechanisms underlying immune-mediated tumor inhibition by combined radiotherapy and immunotherapy.